TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to provide a corporate update following its recently announced sale of the Company's Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP (the "Ketamine ANDA"). The transaction was a strategic sale of a single generic ketamine asset and the sale did not include PharmaTher's broader ketamine portfolio. The Company continues to own its ketamine-based programs, including for Parkinson's disease, amyotrophic lateral sclerosis (ALS), complex regional pain syndrome (CRPS), as well as its ketamine microneedle patch and wearable pump programs for mental health, neurological, and pain disorders.